We also discovered that the PDL-1 checkpoints were reversed, implying that patients with hyper-risk ccRCC and the C2 subtype may benefit from immunotherapy, while those with hypo-risk ccRCC and the C1 subtype may be more sensitive to anti-PDL-1. Here, CD274 is linked to nonpapillary renal cell carcinoma.